ANGO
AngioDynamics, Inc.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$15.05
−2.75%Jul 14, 2026, 12:21 UTC
AngioDynamics reported its fiscal fourth quarter 2026 financial results, posting a net loss of $0.07 per share, which beat the Zacks Consensus Estimate of a loss of $0.11 per share.
Jun 18, 2026, 14:55 UTC
AngioDynamics received FDA IDE approval for its NanoKnife BPH feasibility study.
Source:Jun 17, 2026, 12:30 UTC
AngioDynamics received FDA IDE approval for the RELIEF feasibility study evaluating its NanoKnife IRE platform for treating benign prostatic hyperplasia.
Source: